Strategy

Apr 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Too often in M&A or product-linked carve-outs, executives overlook the complexities of disentangling operations and the effort required for regulatory re-registration and labeling changes.
Mar 12, 2012
Pharmaceutical Executive
With growth as its guiding light, Novartis has big plans for the emerging markets. Pharm Exec sits down with CEO Joe Jimenez to understand what it will take the company to best the competition.
Mar 01, 2012
Pharmaceutical Executive
Making real connections that resonate with audiences in a digital world is a fine art, especially in the heavily regulated world of Big Pharma
Mar 01, 2012
Pharmaceutical Executive
Our annual press audit finds that the big news in 2011 for pharma was ... no news.
Feb 01, 2012
Pharmaceutical Executive
Pharm Exec's Brand of the Year: Abbott's Humira
Feb 01, 2012
Pharmaceutical Executive
Pharm Exec speaks to Bausch + Lomb CEO Brent Saunders about how he turned around "a very troubled company".
Jan 01, 2012
Pharmaceutical Executive
Pharma has become unusually quick to strike embrace the iPad. But the industry's inherent conservatism means it has some way to go to fully milk the device's potential.
Jan 01, 2012
Pharmaceutical Executive
The challenge for 2012 is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap.
Jan 01, 2012
Pharmaceutical Executive
Mason Tenaglia offers empirical defense of coupons and copay offset programs.
Jan 01, 2012
Pharmaceutical Executive
Pharma must coordinate the efforts of medical, legal, HR, global partners and many other players in the regulatory compliance space to keep itself afloat in choppy seas.
native1_300x100
lorem ipsum